Atopic Dermatitis: How Cynomolgus Monkey Models Advance Precision Therapeutics

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that affects millions worldwide, significantly impairing quality of life. Characterized by intense itching, recurrent eczematous lesions, and skin barrier dysfunction, AD's pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental factors.

While existing treatments-such as corticosteroids and calcineurin inhibitors-offer symptomatic relief, they come with drawbacks including long-term side effects, limited efficacy in some patient subsets, and high costs for biologics. The need for safer, more targeted therapies is driving preclinical innovation.

This article highlights Prisys Biotech's advanced cynomolgus monkey model of AD and how it provides a valuable translational platform for evaluating novel therapeutic strategies.

Atopic dermatitis is typified by:

Skin barrier impairment (e.g., increased transepidermal water loss [TEWL]),

Th2-skewed immune responses, marked by elevated IL-4, IL-13, IL-31, and TSLP,

Elevated IgE levels and allergen sensitization,

Severe pruritus, which contributes to the itch-scratch cycle and skin damage.

Conventional treatments, though effective in mild cases, are often inadequate for moderate-to-severe AD. Topical corticosteroids and immunomodulators have adherence issues and potential long-term toxicity. Biologics-while promising-are costly and often limited to certain patient populations.

This underscores the need for preclinical models that can mimic the chronicity, immune heterogeneity, and clinical endpoints of human AD.

Non-human primates (NHPs), particularly cynomolgus monkeys, offer several key advantages for dermatological research:

• Skin anatomy and physiology: NHPs share a similar epidermal and dermal structure with humans, including hair follicle density and sebaceous gland distribution, allowing for more accurate modeling of barrier dysfunction.
• Immune system fidelity: Cynomolgus monkeys exhibit human-like immune responses, such as IgE production, Th2 cytokine expression, and infiltration of eosinophils and mast cells.
• Behavioral relevance: Observable scratching behavior in NHPs serves as a quantifiable readout for pruritus, a hallmark symptom often difficult to assess in rodents.
• Limitations of rodent models: While useful, many murine AD models fail to replicate chronic inflammation and the full spectrum of human immune responses, limiting their translational value.

Prisys Biotech has developed a robust OVA-induced AD model in cynomolgus monkeys that recapitulates the human disease course in multiple dimensions.

Model Induction Strategy:

• Sensitization phase: Achieved through OVA administration or aerosol inhalation to activate the immune system's initial sensitization to allergens.
• Challenge phase: Sustained cutaneous exposure to OVA triggers AD-like symptoms and maintains chronic inflammation.

Key Evaluation Endpoints:

• Clinical scoring: Adapted from the EASI system to evaluate erythema, scaling, excoriation, and lesion severity.
• Skin barrier function: Quantified by measuring TEWL.
• Histopathology: Assesses epidermal hyperplasia, eosinophilic and lymphocytic infiltration, and mast cell activation.
• Biomarker quantification: Serum IgE, IL-4, IL-13, and IFN-γ levels offer insight into systemic immune activation.
• Behavioral monitoring: Scratching frequency (AI-based NHP Behavior Analysis System) and severity are recorded to assess pruritus and treatment efficacy.
• Skin microbiome profiling: Tracks shifts in skin microbial composition-a rising focus in AD pathogenesis research.
• Pulmonary function testing: In models presenting co-morbid asthma, response to acetylcholine (ACh) and OVA inhalation is evaluated, highlighting the model's capacity to explore the "atopic march."

Therapeutic Applications:

Prisys's model enables efficacy and safety testing for various drug classes, including:

• Monoclonal antibodies targeting Th2 pathways (e.g., IL-4/IL-13),
• Anti-pruritic agents acting on IL-31 signaling,
• Barrier-enhancing topical formulations,
• Microbiome-modulating treatments.

By replicating critical features of human AD, Prisys's cynomolgus monkey model provides high-fidelity endpoints-such as TEWL, EASI-like scoring, and cytokine profiling-that align closely with clinical trial metrics. This enhances the predictability of preclinical findings and reduces the risk of late-stage clinical failure.

Moreover, the model's capacity to explore co-morbidities such as asthma adds value in investigating systemic aspects of the atopic syndrome and informing broader therapeutic strategies.

Prisys Biotech's cynomolgus monkey AD model offers a powerful and versatile tool for preclinical researchers aiming to develop innovative and targeted therapies for atopic dermatitis. Through detailed immunological, behavioral, and pathological characterization, the model supports translational research with strong clinical relevance.

Partner with Prisys Biotech to leverage our state-of-the-art NHP model platform and accelerate the discovery of next-generation AD therapies that truly benefit patients.

Contact us today to learn how our cynomolgus monkey AD model can empower your drug development program.